linjc16/ctgov huggingface dataset:
Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters

Study Overview
=================
Brief Summary
-----------------
This study evaluates different optimized MRI sequences for the detection of brain lesions in patients with multiple sclerosis in comparison with the recommended FLAIR sequence

Detailed Description
-----------------
MRI is a tool of choice for detecting demyelinating lesions in Multiple Sclerosis (MS) disease. On a consensual basis, the detection of those lesions in done on FLAIR (FLuid Attenuated Inversion Recovery) sequences, weighted T2 with cancelling of fluid signal, leading to a much better contrast between the lesion and the environment. The environment is displayed as a iso-signal for the surrounding healthy brain's white matter and as a hypo-signal for the fluids. Keys parameters indicative of the sequence's contrast are the echo time, the reversal time, and the repetition time, wich seems to be crucial to detect the lesions, according to relatively discordant results of publications using different technologies of FLAIR. Although 3D FLAIR sequences play an essential role for diagnosis and evaluation (evolution under treatment, prognosis) of demyelinating pathologies there is no consensus on parameters used on routine basis. The aim of the trial is to discover the optimal combination of theses parameters so as to well detect the lesions.

Official Title
-----------------
Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: relapsing remitting multiple sclerosis MRI required Exclusion Criteria: MRI contraindication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of detectable lesions | quantification of lesions on each sequence | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| localisation of lesions | proportion of lesions localised in cerebellum or brainstem, on each sequence | baseline |
68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease

Study Overview
=================
Brief Summary
-----------------
To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/ computed tomography (PET/CT) for the diagnosis and prognosis in fibrotic disease

Detailed Description
-----------------
Subjects with fibrotic disease underwent 68Ga-FAPI-04 PET/CT scanning. Fibrosis lesion uptake was quantified by the maximum standard uptake value (SUVmax). Subjects also received the conventional clinical assessment for liver fibrosis, such as magnetic resonance imaging(MRI) , biopsy and blood biochemical indexes (BBI) testing. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-FAPI-04 PET/CT, MRI and BBI were calculated and compared to evaluate the diagnostic efficacy.

Official Title
-----------------
68Ga-DOTA/NOTA-FAPI PET/CT in Patients With Various Fibrotic Disease

Conditions
-----------------
Fibrosis, Positron-Emission Tomography

Intervention / Treatment
-----------------
* Drug: 68Ga-FAPI-04


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients (aged 18 years or order) patients with suspected or new diagnosed fibrotic disease (supporting evidence may include , BBI, MRI, CT and pathology report) patients who had scheduled 68Ga-FAPI-04 PET/CT scan patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee Exclusion Criteria: patients with pregnancy the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 68Ga-FAPI-04<br>Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time. | Drug: 68Ga-FAPI-04<br>* Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Standardized uptake value (SUV) | Standardized uptake value (SUV) of 68Ga-DOTA/NOTA-FAPI-04 for each target lesion of subject. | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic efficacy | The sensitivity, specificity and accuracy of 68Ga-DOTA/NOTA-FAPI-04 PET/CT were calculated. | 30 days |
Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency

Study Overview
=================
Brief Summary
-----------------
While vitamin D supplementation is safe and effective in repleting vitamin D levels in dialysis patients, the impact on anemia is unknown. The majority of hemodialysis patients require erythropoietin supplementation to maintain their serum hemoglobin between 11 and 12 gm/dL, a drug that is both costly and associated with significant side effects. If repletion of vitamin D significantly decreases erythropoietin requirements in hemodialysis patients, it would result in a substantial reduction in patient care costs. Our aim is to study the impact of ergocalciferol supplementation in hemodialysis patients with 25-hydroxyvitamin D deficiency. The investigators anticipate approximately 30% reduction in erythropoietin dose requirement in our hemodialysis population.

Official Title
-----------------
Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency

Conditions
-----------------
Vitamin D Deficiency, Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All hemodialysis patients at the Kaiser Permanente Los Angeles Medical Center with vitamin D deficiency [defined by 25-hydroxyvitamin D level less than 30 ng/ml] Exclusion Criteria: Non-renal causes of anemia (myelodysplastic syndrome, multiple myeloma, pure red cell aplasia, thallassemia, and sickle cell anemia) Active cancer AIDS refused erythropoeitin, intravenous iron or vitamin D analogs in the past no erythropoeitin requirement for greater than 6 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| erythropoietin dosage |  | 6 months |
Intravitreal Injections of Melphalan for Retinoblastoma

Study Overview
=================
Brief Summary
-----------------
Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials. Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan. In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.

Detailed Description
-----------------
Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or with vitreal seeding of the disease.

Official Title
-----------------
Intravitreal Injections of Melphalan for Retinoblastoma

Conditions
-----------------
Retinoblastoma

Intervention / Treatment
-----------------
* Drug: IVit Melphalan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Retinoblastoma that has not responded to chemotherapy Retinoblastoma that has vitreal seeding Exclusion Criteria: previous failure of IVit Melphalan

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IVit Treatment group<br>Intravitreal injections of Melphalan | Drug: IVit Melphalan<br>* IVit injections of Melphalan<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment response | short term response to treatment and long term complications | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | short and long term complications | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinoblastoma
Kinetics of the Finasteride Prostate Induced Apoptosis

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. Prostate histological fragments are conditioned for molecular and histologic studies.

Official Title
-----------------
Kinetics of the Finasteride Prostate Induced Apoptosis

Conditions
-----------------
Benign Prostatic Hyperplasia

Intervention / Treatment
-----------------
* Drug: finasteride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with low tract urinary symptoms needing a surgical procedure No previous treatment with finasteride No androgen deficiency; no prostate cancer suspected.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: finasteride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Date of the maximum apoptosis in the prostate tissues treated by finasteride |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Molecular mechanisms involved in BPH finasteride induced apoptosis |  |  | 
| Decrease in the frequency of the hemorrhagic incidents after the surgical procedure in patients with a treatment using finasteride |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate, apoptosis, finasteride kinetics
Infectious Mediastinitis Among the Strasbourg Universitary Hospital

Study Overview
=================
Brief Summary
-----------------
Mediastinitis are rare but serious infections, with mortality rates varying from 6 to 30% according to the literature. They are essentially linked to surgical management (cardio-thoracic in particular), but some forms can be spontaneous, after extension of an ENT infectious focus, for example. Despite their seriousness, there is no strong recommendations to define their management, especially concerning antibiotic therapy and its duration. The aim of this research is to make a descriptive analysis of the cases of mediastinitis at HUS in recent years, and to study the therapeutic strategy used

Official Title
-----------------
Infectious Mediastinitis Among the Strasbourg Universitary Hospital, a Retrospective Cohort

Conditions
-----------------
Mediastinitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥18 years old) Subject diagnosed with mediastinitis between 01/01/2010 and 31/12/2020 Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. Exclusion Criteria: Subject having expressed opposition to participate in the study Subject under guardianship, curatorship or safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of the cases of mediastinitis and the therapeutic strategy used in recent years at University Hospitals of Strasbourg |  | Files analysed retrospectively from January 01, 2010 to December 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mediastinitis, Sternitis, Deep Sternal Wound Infection
Race-Specific Propofol Titration to Effect for Procedural Sedation

Study Overview
=================
Brief Summary
-----------------
Prospectively evaluate newly established guidelines and make clinicians aware of inter-racial difference in propofol sensitivity.

Detailed Description
-----------------
The primary motivation in conducting this study is to conduct the implementation science, i.e., formalize and train, and retrain if needed, anesthesia providers in the standard practice of titrating infusion rate to effect and clinically evaluate the effect of race and ethnicity on propofol monotherapy sedation during GI endoscopy. The ultimate goal is to make it less likely that patients from races known to be sensitive to propofol experience inadvertent overdosing.

Official Title
-----------------
Pragmatic Clinical Trial of Race-Specific Response to Propofol Infusion Titrated to Effect for Procedural Sedation During Endoscopy

Conditions
-----------------
Unconsciousness, Apnea, Postanesthetic, Sedative Overdose, Hypoxemia

Intervention / Treatment
-----------------
* Procedure: Titrate propofol monotherapy infusion to effect


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing propofol sedation at Gainesville (GNV) and Jacksonville (JAX) GI Endoscopy suites Age range 18 - 80 years old Patients whose race can be identified from the electronic patient information chart (EPIC) Exclusion Criteria: Patients who identify as multiracial in Epic Patients who identify as Other in Epic Patients who refuse to indicate their race in Epic Patients whose race is listed as unknown in Epic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Training intervention<br>Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol. | Procedure: Titrate propofol monotherapy infusion to effect<br>* Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.<br>|
| Effectiveness of training intervention<br>Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the recovery times among races and ethnicities | Monitored using aggregate data for metrics of recovery times | Change from baseline up to 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Procedural Sedation
Educational Intervention for Optimizing Adolescent Mental Health Screening and Treatment in Pediatric Residency

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is: 1) to assess pediatric resident knowledge of adolescent mental health; 2) to assess pediatric resident comfort level for screening, assessing, and treating mental health disorders in adolescents, and; 3) to evaluate pediatric resident current practices for adolescent mental health screening, assessment, and treatment.

Official Title
-----------------
An Educational Intervention for Optimizing Adolescent Mental Health Screening Skills and Treatment in Pediatric Residency

Conditions
-----------------
Mental Health

Intervention / Treatment
-----------------
* Other: Educational intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric Residents Adolescent Rotation Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Education Intervention<br> | Other: Educational intervention<br>* An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Do pediatric residents lack an adequate knowledge base for screening, assessing, and treating mental health disorders in adolescents? |  | Feb 2008-June 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Are pediatric residents are comfortable with screening, assessing, and treating adolescent mental health disorders. Do pediatric residents use validated verbal or written mental health screening and assessment tools. |  | Feb 2008-June 2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric, Resident, Depression, Screening, Substance Abuse, Pediatric Resident knowledge of mental health topics, Pediatric Resident current practices for screening and treating mental health disorders, Pediatric Resident mental health care competency
Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.

Official Title
-----------------
Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Other: Physical exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of mild Alzheimer's disease (NINCDS-ADRDA criteria) Taking cholinesterase inhibitors Sedentary Ability to do physical exercise Exclusion Criteria: Parkinson disease Down syndrome Epilepsy or concussion Drug or alcohol abuse Past psychiatric history Vitamin B12 Deficiency Uncontrolled diabetes or thyroid function

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>No intervention | |
| Experimental: Physical exercise<br>A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale). | Other: Physical exercise<br>* A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain Glucose Consumption | Brain glucose uptake (umol/100g/min) using 18F-FDG PET imaging | 3 months | 
| Brain Acetoacetate Consumption | Brain acetoacetate uptake (umol/100g/min) using 11C-AcAc PET imaging | 3 months |